← Human Trials & Peer-Reviewed Studies
Randomized crossover study that used methylene blue or random 4-quadrant biopsy for the diagnosis of dysplasia in Barrett's esophagus
Plain-language guide to PMID 16860068 (2006): crossover randomized controlled trial study of Methylene blue (non-peptide stack partner).
Key Facts
- PMID
- 16860068
- Journal
- Gastrointestinal endoscopy
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Lim CH et al. (4 authors)
- DOI
- 10.1016/j.gie.2005.07.025
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).
The aim of this study was to compare MB directed biopsies (MBDB) with their current standard, which is random 4 quadrant biopsies (RB).
Why It Was Studied
Barrett's esophagus is generally accepted to be a premalignant condition.
Thirty-six percent of eligible patients declined the invitation to participate.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
Patients with a diagnosis of dysplasia identified in Barrett's esophagus within a 2-year period before entering the study.
How the Study Was Run
The design is described as randomized and crossover.
Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.
In the crossover set-up each of the participants took both Methylene blue (non-peptide stack partner) and the comparison in turn, acting as their own control.
The methods mention a period of 2 years.
A randomized prospective crossover study.
Either 4 random quadrant biopsies taken every 2 cm through the length of the Barrett's esophagus or MBDB from unstained or heterogenously stained mucosa.
What Was Measured
Topics PubMed links to this paper include Barrett Esophagus, Biopsy, Coloring Agents, Image Enhancement, Methylene Blue, Mucous Membrane and Sensitivity and Specificity.
What This Means in Plain Language
The paper is a randomized and crossover study of Methylene blue (non-peptide stack partner) over 2 years.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2006 (Gastrointestinal endoscopy), a journal based in United States.
More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.